230615-51-7

Basic information

• Product Name: 2,3,4,5-Tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine
• Synonyms: 1-(10-Aza-tricyclo[6.3.1.0]dodeca-2,4,6-trien-10-yl)-2,2,2-trifluoro-ethanone;Ethanone, 2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-1,5-methano-3H-3-benzazepin-3-yl)-;2,3,4,5-Tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine;2-trifluoro-1-(1;5-Methano-3H-3-benzazepin-3-yl)-;5-tetrahydro-1;Ethanone,2,2,2-thrifluoro-1-(1,2,4,5-tetrahydro -1,5-Methano-3H-3-benzapin-3-yl);1-(10-aza-tricyclo[6.3.1.02,7]dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone
• CAS NO: 230615-51-7
• Molecular Formula: C₁₃H₁₂F₃NO
• Molecular Weight: 255.24
• Mol File: 230615-51-7.mol

Chemical Properties

• Melting Point: 67-68 ºC
• Boiling Point: 381.749 °C at 760 mmHg
• Flash Point: 184.675 °C
• Appearance: /
• Density: 1.333
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.528
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1.82±0.20(Predicted)
• CAS DataBase Reference: 2,3,4,5-Tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4,5-Tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine(230615-51-7)
• EPA Substance Registry System: 2,3,4,5-Tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine(230615-51-7)

Safety Data

• Hazardous Substances Data: 230615-51-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,3,4,5-Tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine is used as a reactant for the preparation of Varenicline, a nicotinic α4β2 acetylcholine receptor partial agonist. Varenicline is an important medication that aids in smoking cessation by reducing the cravings and withdrawal symptoms associated with nicotine dependence. The compound's role in the synthesis of Varenicline highlights its significance in the development of treatments for tobacco addiction and related health issues.

InChI:InChI=1/C13H12F3NO/c14-13(15,16)12(18)17-6-8-5-9(7-17)11-4-2-1-3-10(8)11/h1-4,8-9H,5-7H2

Upstream product

• 230615-52-8 2,3,4,5-tetrahydro-1,5-methylene-1H-3-benzazepine hydrochloride 
• 407-25-0 trifluoroacetic anhydride 
• 357425-93-5 1,5-methano-2,3,4,5-tetrahydro-1H-3-benzazepine p-toluenesulfonic acid salt 
• 69718-72-5 10-Aza-tricyclo[6.3.1.02.7]dodeca-2⁽⁷⁾,3,5-triene 

Downstream Products

• 230615-53-9 1-(4-nitro-10-aza-tricyclo[6.3.1.02,7]dodeca-2(7),3,5-trien-10-yl)-2,2,2-trifluoro-ethanone 
• 230615-59-5 1-(7,8-dinitro-4,5-dihydro-1H-1,5-methanobenzo[d]azepin-3(2H)-yl)-2,2,2-trifluoroethanone 

Relevant articles and documents

PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

Provided herein is an improved, convenient, commercially viable and environmentally friendly process for the preparation of varenicline or a pharmaceutically acceptable salt thereof comprising reacting l-(4,5-diamino-10-aza-tricyclo[6.3.1.02 7]dodeca-2(7),3,5-trien- 10-yl)-2,2,2-trifluoro-ethanone with chloroacetaldehyde in the pressence of an oxygen source. Provided further herein is an improved and industrially advantageous process for the preparation of l-(4,5-diamino-10-aza-tricyclo[6.3.1.02 7]dodeca-2(7),3,5-trien-10-yl)-2,2,2- trifluoro-ethanone.

IMPROVED PROCESSES FOR THE SYNTHESIS OF VARENICLINE L-TARTRATE

This invention provides a process of preparing varenicline L-tartrate salt. This invention also provides varenicline L-tartrate produced by the instant method, as well as a pharmaceutical composition comprising same.

PROCESSES FOR THE PREPARATION OF VARENICLINE AND INTERMEDIATES THEREOF

The invention provides an improved process for the preparation and purification of Varenicline and intermediates for the preparation of Varenicline.

3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation

3,5-Bicyclic aryl piperidines are a new class of high-affinity α4β2 nicotinic receptor agents. We have sought nicotinic receptor partial agonists of the α4β2 nicotinic acetylcholine receptor for smoking cessation, and a number of compounds fulfill potency, selectivity, and efficacy requirements in vitro. In vivo, selected agents demonstrate potent partial agonist efficacy on the mesolimbic dopamine system, a key measure of therapeutic potential for smoking cessation.

Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds

The present invention relates to processes for the preparation of any of the intermediate 1,3-substituted indenes of the formulae (Ia), (Ib) and (Ic) or a mixture thereof: wherein R1, R2, R3, R4, and R5 are defined herein. Compounds of formulae (Ia), (Ib) and (IC) or mixtures thereof are useful in the preparation of compounds of formula (II): wherein R2, R3 and R6 are also defined herein.

Aryl fused azapolycyclic compounds

Compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, R3 and n are defined as in the specification, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders are claimed.